tiprankstipranks
Xeris Pharmaceuticals (DE:2B30)
NASDAQ:2B30
Germany Market
2B30
Xeris Pharmaceuticals
RESEARCH TOOLSreports

Xeris Pharmaceuticals (2B30) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

2B30 Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Xeris
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2B30 Stock 12 Month Forecast

Average Price Target

€10.71
▲(109.14% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Xeris Pharmaceuticals in the last 3 months. The average price target is €10.71 with a high forecast of €15.73 and a low forecast of €7.87. The average price target represents a 109.14% change from the last price of €5.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","9":"€9","16":"€16","5.5":"€5.5","12.5":"€12.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15.73388064,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€15.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.70777988,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€10.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.86694032,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.87</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.5,9,12.5,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.826,7.511221587692307,8.196443175384616,8.881664763076923,9.56688635076923,10.252107938461538,10.937329526153846,11.622551113846153,12.307772701538461,12.992994289230769,13.678215876923076,14.363437464615386,15.048659052307695,{"y":15.73388064,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.826,7.124598452307692,7.423196904615384,7.721795356923077,8.02039380923077,8.318992261538462,8.617590713846154,8.916189166153845,9.21478761846154,9.513386070769231,9.811984523076923,10.110582975384617,10.409181427692308,{"y":10.70777988,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.826,6.906072332307692,6.986144664615384,7.066216996923076,7.146289329230769,7.226361661538461,7.306433993846154,7.386506326153846,7.466578658461539,7.546650990769231,7.626723323076924,7.7067956553846155,7.786867987692308,{"y":7.86694032,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.894,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.382,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.815,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.305,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.19,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.04,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.485,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.928,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.074,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.196,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.826,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€15.73Average Price Target€10.71Lowest Price Target€7.87
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Craig-Hallum Analyst forecast on DE:2B30
Chase Knickerbocker
Craig-Hallum
Craig-Hallum
€10.49
Buy
104.87%
Upside
Assigned
07/08/26
Analysts Are Bullish on These Healthcare Stocks: Alterity Therapeutics (ATHE), Vera Therapeutics (VERA)
Barclays Analyst forecast on DE:2B30
Jenna Davidner
Barclays
Barclays
€7.87
Buy
53.65%
Upside
Assigned
05/13/26
Xeris Pharmaceuticals (XERS) Receives a Buy from Barclays
Oppenheimer Analyst forecast on DE:2B30
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€15.73
Buy
207.30%
Upside
Reiterated
05/08/26
Oppenheimer Sticks to Its Buy Rating for Xeris Pharmaceuticals (XERS)
H.C. Wainwright Analyst forecast on DE:2B30
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€8.74
Buy
70.72%
Upside
Reiterated
05/08/26
H.C. Wainwright Remains a Buy on Xeris Pharmaceuticals (XERS)
Jefferies Analyst forecast on DE:2B30
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€8.74
Buy
70.72%
Upside
Reiterated
01/09/26
Xeris Pharmaceuticals (XERS) Gets a Buy from Jefferies
Piper Sandler Analyst forecast on DE:2B30
David Amsellem
Piper Sandler
Piper Sandler
€5.24→€6.99
Hold
36.58%
Upside
Reiterated
11/07/25
Xeris Biopharma price target raised to $8 from $6 at Piper SandlerXeris Biopharma price target raised to $8 from $6 at Piper Sandler
Leerink Partners Analyst forecast on DE:2B30
Roanna Ruiz
Leerink Partners
Leerink Partners
€6.12→€7.87
Buy
53.65%
Upside
Reiterated
08/20/25
Leerink Partners Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Craig-Hallum Analyst forecast on DE:2B30
Chase Knickerbocker
Craig-Hallum
Craig-Hallum
€10.49
Buy
104.87%
Upside
Assigned
07/08/26
Analysts Are Bullish on These Healthcare Stocks: Alterity Therapeutics (ATHE), Vera Therapeutics (VERA)
Barclays Analyst forecast on DE:2B30
Jenna Davidner
Barclays
Barclays
€7.87
Buy
53.65%
Upside
Assigned
05/13/26
Xeris Pharmaceuticals (XERS) Receives a Buy from Barclays
Oppenheimer Analyst forecast on DE:2B30
Unknown Analyst
Oppenheimer
Not Ranked
Oppenheimer
€15.73
Buy
207.30%
Upside
Reiterated
05/08/26
Oppenheimer Sticks to Its Buy Rating for Xeris Pharmaceuticals (XERS)
H.C. Wainwright Analyst forecast on DE:2B30
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
€8.74
Buy
70.72%
Upside
Reiterated
05/08/26
H.C. Wainwright Remains a Buy on Xeris Pharmaceuticals (XERS)
Jefferies Analyst forecast on DE:2B30
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€8.74
Buy
70.72%
Upside
Reiterated
01/09/26
Xeris Pharmaceuticals (XERS) Gets a Buy from Jefferies
Piper Sandler Analyst forecast on DE:2B30
David Amsellem
Piper Sandler
Piper Sandler
€5.24→€6.99
Hold
36.58%
Upside
Reiterated
11/07/25
Xeris Biopharma price target raised to $8 from $6 at Piper SandlerXeris Biopharma price target raised to $8 from $6 at Piper Sandler
Leerink Partners Analyst forecast on DE:2B30
Roanna Ruiz
Leerink Partners
Leerink Partners
€6.12→€7.87
Buy
53.65%
Upside
Reiterated
08/20/25
Leerink Partners Sticks to Their Buy Rating for Xeris Pharmaceuticals (XERS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ENOVEnovis
GKOSGlaukos
MGTXMeiragtx Holdings
TECXTectonic Therapeutic
STOKStoke Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xeris Pharmaceuticals

3 Months
Leland GershellOppenheimer
Success Rate
8/10 ratings generated profit
80%
Average Return
+11.45%
Copying Leland Gershell's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +11.45% per trade.
1 Year
Chase KnickerbockerCraig-Hallum
Success Rate
21/22 ratings generated profit
95%
Average Return
+61.75%
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 95.45% of your transactions generating a profit, with an average return of +61.75% per trade.
2 Years
Chase KnickerbockerCraig-Hallum
Success Rate
21/22 ratings generated profit
95%
Average Return
+131.86%
Copying Chase Knickerbocker's trades and holding each position for 2 Years would result in 95.45% of your transactions generating a profit, with an average return of +131.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2B30 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
2
3
6
4
3
Buy
6
2
2
3
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
5
8
7
7
In the current month, 2B30 has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2B30 average Analyst price target in the past 3 months is 10.71.
Each month's total comprises the sum of three months' worth of ratings.

2B30 Financial Forecast

2B30 Earnings Forecast

Next quarter’s earnings estimate for 2B30 is €0.01 with a range of >-€0.01 to €0.04. The previous quarter’s EPS was <€0.01. 2B30 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 2B30 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 2B30 is €0.01 with a range of >-€0.01 to €0.04. The previous quarter’s EPS was <€0.01. 2B30 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 2B30 has Performed in-line its overall industry.

2B30 Sales Forecast

Next quarter’s sales forecast for 2B30 is €79.16M with a range of €77.99M to €80.80M. The previous quarter’s sales results were €73.01M. 2B30 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 2B30 has Performed in-line its overall industry.
Next quarter’s sales forecast for 2B30 is €79.16M with a range of €77.99M to €80.80M. The previous quarter’s sales results were €73.01M. 2B30 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 2B30 has Performed in-line its overall industry.

2B30 Stock Forecast FAQ

What is DE:2B30’s average 12-month price target, according to analysts?
Based on analyst ratings, Xeris Pharmaceuticals’s 12-month average price target is 10.71.
    What is DE:2B30’s upside potential, based on the analysts’ average price target?
    Xeris Pharmaceuticals has 109.14% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Xeris Pharmaceuticals a Buy, Sell or Hold?
          Xeris Pharmaceuticals has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Xeris Pharmaceuticals’s share price target?
            The average share price target for Xeris Pharmaceuticals is 10.71. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €15.73 ,and the lowest forecast is €7.87. The average share price target represents 109.14% Increase from the current price of €5.12.
              What do analysts say about Xeris Pharmaceuticals?
              Xeris Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Xeris Pharmaceuticals?
                To buy shares of DE:2B30, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.